A randomized phase ll study consisting S-1 + CDDP (SP) and Capecitabin + CDDP (XP) for adversed/metastatic gastric cancer with mesurable lesions and HER2 negative tumor (HERBIS-4A).

Trial Profile

A randomized phase ll study consisting S-1 + CDDP (SP) and Capecitabin + CDDP (XP) for adversed/metastatic gastric cancer with mesurable lesions and HER2 negative tumor (HERBIS-4A).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 May 2018

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms HERBIS-4A
  • Most Recent Events

    • 20 Jan 2018 Primary endpoint (Response rate) has not been met, according to the results presented at the 2018 Gastrointestinal Cancers Symposium
    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
    • 30 Jun 2016 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top